No Data
No Data
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Merck Downgraded by Truist to Hold Over Growth Concerns
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $298
Amgen Analyst Ratings